Recent Updates
Recently added Catalysts

BMS-791826

Phase 1

Immunoscience | Small molecule | Other |Bristol-Myers Squibb Company|Last Updated: Jun 9, 2020

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment120
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03198013A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy MalesPHASE1 COMPLETED 120Nov 11, 2008May 18, 2009Jun 9, 20201 Australia
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Incidence of Adverse Events (AEs)
Up to 34 days

safety and tolerability

Incidence of serious adverse events (SAEs)
Up to 34 days

safety and tolerability

Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
Module AEXPERIMENTALSingle Ascending Dose
Module BEXPERIMENTALMultiple Ascending Dose
Interventions
NameTypeDescription
PrednisoloneDRUGSpecified dose on specified days
BMS-791826DRUGSpecified dose on specified days
PlaceboDRUGSpecified dose on specified days
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexMALE
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Healthy male subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations * Body Mass Index (BMI) of 18 to 30 kilogram / square meter (kg/m2), inclusive * S...

Countries:Australia
Unlock Eligibility Criteria